Immunovia offers an update on its new lab in Research Triangle Park, USA. Immunovia announced on 29 April the company's plans to streamline its lab operations and move to Research Triangle Park (RTP), following the successful model development study of the next generation test. After taking occupancy on 21 May 2024, Immunovia is announcing that its lab is fully operational and staffed.

All lab equipment is installed and validated. Systems for document control and quality management have been implemented. The new lab is also fully staffed following the hiring of two new scientists.

The protein assays for Immunovia's next-generation test, developed in collaboration with Immunovia's partner Proteomedix, have been successfully transferred to the lab. The assays are performed on an ELISA platform and are faster, cheaper, and less-labor intensive than Immunovia's prior proprietary IMMray platform. Under the leadership and direction of Dr. Lisa Ford, the team in Research Triangle Park will focus next on confirming the analytical validity of these assays.

Immunovia's team will validate the assays according to relevant regulatory guidance, including CAP, CLIA and CLSI. The lab will then conduct a large clinical validation study of the next-generation test in the fourth quarter of 2024. Immunovia has filed to transfer its CLIA license from the lab in Marlborough to the new lab in Research Triangle Park.

The company will also be renewing its accreditation with the College of American Pathology (CAP).